“…A targeted approach was used to select other biomarkers, based on their previously demonstrated direct or indirect pro-fibrotic effects, or based on their proven relevance as diagnostic and/or prognostic biomarkers in human IPF. Those biomarkers included procollagen type III amino terminal pro-peptide (PIIINP) (Heikkilä et al, 2013), endothelin-1 (ET-1) (Krafft et al, 2011), transforming growth factor beta-1 (TGF-β1) (Krafft et al, 2014), CCL2 (Roels et al, 2015a,b), IL-8 (Roels et al, 2015a,b), 5-hydroxytryptamine-serotonin (5-HT) (Roels et al, 2015a), vascular endothelial growth factor (VEGF) (Roels et al, 2015a), Krebs Von den Lungen-6 (KL6) (Fastrès et al, 2018) and C-reactive-protein (CRP) (Viitanen et al, 2014). Among those biomarkers, CCL2, IL-8, ET-1 and PIIINP were elevated in the BALF of WHWTs with CIPF compared with healthy WHWTs, while only CCL2 and ET-1 were elevated in the serum of affected WHWTs compared with healthy WHWTs (Krafft et al, 2011;Heikkilä et al, 2013;Roels et al, 2015a,b).…”